BRPI0511029A - ácido 2-{[2-(2-metil amino-pirimidin-4-il)-1h-indol-5-carbonil]-amino}-3-(feni l piridin-2-il-amino)-propiÈnico substancialmente puro como um inibidor da i capa b quinase - Google Patents

ácido 2-{[2-(2-metil amino-pirimidin-4-il)-1h-indol-5-carbonil]-amino}-3-(feni l piridin-2-il-amino)-propiÈnico substancialmente puro como um inibidor da i capa b quinase

Info

Publication number
BRPI0511029A
BRPI0511029A BRPI0511029-7A BRPI0511029A BRPI0511029A BR PI0511029 A BRPI0511029 A BR PI0511029A BR PI0511029 A BRPI0511029 A BR PI0511029A BR PI0511029 A BRPI0511029 A BR PI0511029A
Authority
BR
Brazil
Prior art keywords
amino
indol
pyrimidin
carbonyl
substantially pure
Prior art date
Application number
BRPI0511029-7A
Other languages
English (en)
Inventor
El-Bdaouil Haddad
Olaf Ritzeler
David Johnus Aldous
Paul Joseph Cox
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of BRPI0511029A publication Critical patent/BRPI0511029A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

áCIDO 2-{¢2-(2-METIL AMINO-PIRIMIDIN-4-IL)-1 H-INDOL-5-CARBONIL!-AMINO}-3-(FENIL PIRIDIN-2-IL-AMINO)-PROPIÈNICO SUBSTANCIALMENTE PURO COMO UM INIBIDOR DA I CAPA B QUINASE. A presente invenção refere-se ao composto substancialmente puro de acordo com a fórmula (A): ou um sal farmaceuticamente aceitável, ou solvato do dito composto; referese a uma composição farmacêutica que compreende uma quantidade farmaceuticamente eficaz do composto de acordo com a fórmula (A), e um veículo farmaceuticamente aceitável; e o uso de um composto de acordo com a fórmula (A) possuindo atividade como um inibidor, preferivelmente um inibidor seletivo, da IkB (IKK), particularmente de IKK-2, e aos métodos relacionados aos mesmos.
BRPI0511029-7A 2004-05-12 2005-05-11 ácido 2-{[2-(2-metil amino-pirimidin-4-il)-1h-indol-5-carbonil]-amino}-3-(feni l piridin-2-il-amino)-propiÈnico substancialmente puro como um inibidor da i capa b quinase BRPI0511029A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57014604P 2004-05-12 2004-05-12
PCT/US2005/016381 WO2005113544A1 (en) 2004-05-12 2005-05-11 Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an ikb kinase inhibitor

Publications (1)

Publication Number Publication Date
BRPI0511029A true BRPI0511029A (pt) 2007-11-27

Family

ID=34969825

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511029-7A BRPI0511029A (pt) 2004-05-12 2005-05-11 ácido 2-{[2-(2-metil amino-pirimidin-4-il)-1h-indol-5-carbonil]-amino}-3-(feni l piridin-2-il-amino)-propiÈnico substancialmente puro como um inibidor da i capa b quinase

Country Status (23)

Country Link
EP (1) EP1747215A1 (pt)
JP (1) JP2007537266A (pt)
KR (1) KR20070011483A (pt)
CN (1) CN1950359A (pt)
AR (1) AR049274A1 (pt)
AU (1) AU2005245834A1 (pt)
BR (1) BRPI0511029A (pt)
CA (1) CA2566213A1 (pt)
EC (1) ECSP066992A (pt)
GT (1) GT200500111A (pt)
IL (1) IL178992A0 (pt)
MA (1) MA28553B1 (pt)
MX (1) MXPA06012870A (pt)
NO (1) NO20065719L (pt)
PA (1) PA8633101A1 (pt)
PE (1) PE20060269A1 (pt)
RU (1) RU2006143758A (pt)
SV (1) SV2006002111A (pt)
TN (1) TNSN06338A1 (pt)
TW (1) TW200605881A (pt)
UY (1) UY28897A1 (pt)
WO (1) WO2005113544A1 (pt)
ZA (1) ZA200608712B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE102004033406A1 (de) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
RU2499592C2 (ru) 2008-04-21 2013-11-27 Отономи, Инк. Фармацевтическая композиция для лечения ушных заболеваний
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011134140A1 (en) * 2010-04-27 2011-11-03 Hutchison Medipharma Limited Pyrimidinyl indole compounds
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR20190024983A (ko) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도
CN106588803A (zh) * 2016-11-16 2017-04-26 西南科技大学 一种制备5‑乙酰基异噁唑的新方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
SV2006002111A (es) 2006-01-30
NO20065719L (no) 2006-12-12
MXPA06012870A (es) 2007-02-15
ECSP066992A (es) 2006-12-29
WO2005113544A1 (en) 2005-12-01
TW200605881A (en) 2006-02-16
CN1950359A (zh) 2007-04-18
PE20060269A1 (es) 2006-05-11
KR20070011483A (ko) 2007-01-24
TNSN06338A1 (en) 2008-02-22
IL178992A0 (en) 2007-03-08
GT200500111A (es) 2006-05-09
ZA200608712B (en) 2008-06-25
AU2005245834A1 (en) 2005-12-01
PA8633101A1 (es) 2006-01-23
AR049274A1 (es) 2006-07-12
CA2566213A1 (en) 2005-12-11
MA28553B1 (fr) 2007-04-03
UY28897A1 (es) 2005-12-30
JP2007537266A (ja) 2007-12-20
EP1747215A1 (en) 2007-01-31
RU2006143758A (ru) 2008-06-27

Similar Documents

Publication Publication Date Title
BRPI0511029A (pt) ácido 2-{[2-(2-metil amino-pirimidin-4-il)-1h-indol-5-carbonil]-amino}-3-(feni l piridin-2-il-amino)-propiÈnico substancialmente puro como um inibidor da i capa b quinase
AR106237A2 (es) Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables
CO6231036A2 (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
HK1133596A1 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
AR081226A1 (es) Polimorfo cristalino de 4-[5-[3-cloro-5-(trifluorometil)fenil]-4,5-dihidro-5-(trifluorometil)-3-isoxazolil]-n-[2-oxo-2-[(2,2,2-trifluoroetil)amino]etil]-1-naftalenocarboxamida
ECSP088875A (es) Tienopirimidinas con actividad inhibidora de mnk1/mnk2 para composiciones farmacéuticas
AR061974A1 (es) Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion
MX337906B (es) Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
BRPI0809542A8 (pt) Compostos derivados de indol tendo atividade de inibição de cpla2, composição farmacêutica, e métodos de produção dos referidos compostos
BRPI0618362A2 (pt) sais farmacêuticos inovadores e polimorfos de um inibidor de fator xa
EA200900136A1 (ru) Пирролопиримидины для фармацевтических композиций
UY32072A (es) Tienopirimidinas para composiciones farmacéuticas
PE20091316A1 (es) Compuestos derivados de piridina como inhibidores de cinasa alk-5
BR112013009935B8 (pt) Compostos
BRPI1013821A8 (pt) piridinas substituídas como antagonistas de ccr3.
EA200970156A1 (ru) Пиридизиноновые производные
BR112012007069A2 (pt) derivado de fenol
DK2020996T3 (da) Fremgangsmåder og sammensætninger til behandling af hæmatologiske sygdomme
ATE404536T1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
AR062797A1 (es) Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas.
UY30387A1 (es) Nuevos compuestos
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
AR057909A1 (es) Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
EA200970041A1 (ru) Ингибиторы акт (протеинкиназы в)

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.